3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Lymphoma, Mantle-Cell
5
Recurrence
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Burkitt Lymphoma
2
Waldenstrom Macroglobulinemia
1
Lymphoma, B-Cell
1
Leukemia, Hairy Cell
1
Interventions
Rituximab
57
Cyclophosphamide
42
fludarabine phosphate
29
Peripheral Blood Stem Cell Transplantation
29
Mycophenolic Acid
22
Dexamethasone
21
Tacrolimus
20
Whole-Body Irradiation
18
Bortezomib
18
Cyclosporine
15
Busulfan
13
ibrutinib
12
Methotrexate
12
Melphalan
12
Radiotherapy
11
Etoposide
11
Antilymphocyte Serum
10
zanubrutinib
9
Calcium Dobesilate
9
venetoclax
7
Sirolimus
7
idelalisib
6
Prednisone
6
Lenalidomide
6
Filgrastim
6
Doxorubicin
6
Cyclosporins
6
Bendamustine Hydrochloride
6
Alemtuzumab
6
sargramostim
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Waldenstrom Macroglobulinemia
×
brexucabtagene autoleucel
×
Clear all
NCT05537766
2026-03-10
ZUMA-25
Gilead Sciences
Phase 2
Terminated
19 enrolled
28 charts